EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) met recently to discuss the progress made and to agree on the next steps in the coordinated response to the ongoing shortages of antibiotic medicines containing amoxicillin (alone and in combination with clavulanic acid) in the EU. The MSSG is made up of representatives from EMA, the European Commission and the Heads of Medicines Agencies (HMA).
A recent surge in respiratory infections has driven an increase in demand for amoxicillin which combined with other issues including manufacturing delays and production capacity challenges led to shortages affecting the majority of Member States.
The MSSG and its working party, the SPOC working party, have been closely monitoring the situation since November 2022 and have been engaging with key players in the supply chain of amoxicillin to take forward possible mitigating measures. Data are being provided by Member States through the SPOC WP, by industry associations, as well as stakeholders, allowing a clear and up-to-date understanding of the current situation.1
Click here to read more about the EMA’s response to the shortage of antibiotics in Europe.
References
- E. (2023a, February 6). EMA update on shortages of antibiotics in the EU – European Medicines Agency. European Medicines Agency. https://www.ema.europa.eu/en/news/ema-update-shortages-antibiotics-eu
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
